When you look into the prospect of your product in a global context, all goes smooth unless there are stricter compliances to adhere to.
Regulatory compliances are deeply impacting the Pharmaceutical Manufacturers not only in US but across the globe. US FDA has recently issued observations to many of the major Pharmaceutical Manufacturers in India. The “Big 3” pharmaceutical distributors that handle most of the drug distribution in the United States will also not accept non-serialized returned products, also known as saleable returns, after November 27, 2020.
There is a lot at stake, but the industry is gearing up for the big game.